Adlai Nortye reports $231.9 million in cash and short-term investments at June 30, 2026, up from $8.1 million six months earlier, after two private placements of $140 million and $150 million before fees, and it has de-prioritized AN4005 as a monotherapy.
Adlai Nortye's Phase III BURAN trial of buparlisib missed its overall survival endpoint, the company is dropping the drug, and it plans to cut staff "to preserve cash," with the release giving no survival figures.
Latest balance sheet, Dec 31, 2024 (20-F/A): cash and equivalents $60.9 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Adlai Nortye Group
Has Adlai Nortye Group raised money recently?
Our latest story on this, dated Aug 14, 2026: "Adlai Nortye reports US$231.9 million cash after two 2026 private placements". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Adlai Nortye Group?
Adlai Nortye Group Ltd. trades under the ticker ANL on NASDAQ.
Where is Adlai Nortye Group listed?
Adlai Nortye Group Ltd. is listed on NASDAQ.
What is the SEC CIK of Adlai Nortye Group?
The SEC Central Index Key (CIK) for Adlai Nortye Group Ltd. is 1944552. Its filings are on SEC EDGAR.
Which country or territory is Adlai Nortye Group listed under?
Our directory records Adlai Nortye Group Ltd. under China.
What does Adlai Nortye Group do?
Our directory classifies Adlai Nortye Group Ltd. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
What is the ISIN of Adlai Nortye Group?
The ISIN recorded for Adlai Nortye Group Ltd. is US00704R1095.
Does aibio.space cover Adlai Nortye Group?
aibio.space lists Adlai Nortye Group Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Adlai Nortye Group incorporated?
SEC records list its state or country of incorporation as DE.
Is Adlai Nortye Group profitable?
Adlai Nortye Group Ltd. reported a net loss of $51.9 million for the fiscal year ended Dec 31, 2024, and used $51.8 million of cash in operations, per its annual report to the SEC.
How much does Adlai Nortye Group spend on research and development?
$44.9 million in the fiscal year ended Dec 31, 2024, per its annual report.
How much cash does Adlai Nortye Group have?
$60.9 million in cash at Dec 31, 2024, per its 20-F/A.
What is the latest Adlai Nortye Group (ANL) stock news?
Our latest story on Adlai Nortye Group, dated Aug 14, 2026: "Adlai Nortye reports US$231.9 million cash after two 2026 private placements". Adlai Nortye reports $231.9 million in cash and short-term investments at June 30, 2026, up from $8.1 million six months earlier, after two private placements of $140 million and $150 million before fees, and it has de-prioritized AN4005 as a monotherapy. Source.
Is Adlai Nortye Group in financial distress?
Our latest distress story, dated May 30, 2025: "Adlai Nortye drops buparlisib after Phase III miss, plans workforce cut to preserve cash". Adlai Nortye's Phase III BURAN trial of buparlisib missed its overall survival endpoint, the company is dropping the drug, and it plans to cut staff "to preserve cash," with the release giving no survival figures. Source.
Is Adlai Nortye Group a smaller reporting company?
SEC records list Adlai Nortye Group Ltd.'s filer category as: Non-accelerated filer<br>Emerging growth company.
Investor discussion: Adlai Nortye Group
Members talk about Adlai Nortye Group (ANL). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Adlai Nortye Group, newest first. Each line links the filing it comes from.
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ANL on TradingView.
SEC filings and registration
SEC name
Adlai Nortye Group Ltd.
CIK
1944552
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
ANL (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Emerging growth company
Business address
77 ROBINSON ROAD, #20-01, SINGAPORE, 068896
Phone
848-230-7430
Former names
Adlai Nortye Ltd.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Adlai Nortye Group Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ANL, recorded under China. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio